PL3253874T3 - Leczenie dystrofii twarzowo-łopatkowo-ramieniowej - Google Patents
Leczenie dystrofii twarzowo-łopatkowo-ramieniowejInfo
- Publication number
- PL3253874T3 PL3253874T3 PL16703768.8T PL16703768T PL3253874T3 PL 3253874 T3 PL3253874 T3 PL 3253874T3 PL 16703768 T PL16703768 T PL 16703768T PL 3253874 T3 PL3253874 T3 PL 3253874T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- facioscapulohumeral dystrophy
- facioscapulohumeral
- dystrophy
- Prior art date
Links
- 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 title 1
- 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3183—Diol linkers, e.g. glycols or propanediols
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/532—Closed or circular
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Display Devices Of Pinball Game Machines (AREA)
- External Artificial Organs (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305184 | 2015-02-06 | ||
| PCT/EP2016/052652 WO2016124793A1 (en) | 2015-02-06 | 2016-02-08 | Treatment of facioscapulohumeral dystrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3253874T3 true PL3253874T3 (pl) | 2022-09-12 |
Family
ID=52477752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16703768.8T PL3253874T3 (pl) | 2015-02-06 | 2016-02-08 | Leczenie dystrofii twarzowo-łopatkowo-ramieniowej |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10385338B2 (pl) |
| EP (1) | EP3253874B1 (pl) |
| AU (1) | AU2016214244B2 (pl) |
| CA (1) | CA2975750C (pl) |
| ES (1) | ES2918975T3 (pl) |
| IL (1) | IL253773B (pl) |
| PL (1) | PL3253874T3 (pl) |
| WO (1) | WO2016124793A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ762856A (en) | 2017-10-05 | 2020-07-31 | Fulcrum Therapeutics Inc | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| EP3746082A4 (en) * | 2018-02-02 | 2021-12-08 | Fred Hutchinson Cancer Research Center | METHOD OF TREATMENT OF FACIOUS CAPULOHUMERAL MUSCULAR DYSTROPHY |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3636778B1 (en) * | 2010-08-18 | 2022-01-12 | Fred Hutchinson Cancer Research Center | Agents for use in treating facioscapulohumeral dystrophy (fshd) |
| WO2012038832A2 (en) * | 2010-09-24 | 2012-03-29 | Institut Pasteur | Generation of replicating chimeric measles virus - retrovirus particles |
| CA2842798C (en) | 2011-07-25 | 2021-02-23 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of dux4 |
| CA2843636A1 (en) * | 2011-07-29 | 2013-02-07 | Fred Hutchinson Cancer Research Center | Methods and compositions for modulating the innate immune response and/or myogenesis in a mammalian subject |
-
2016
- 2016-02-08 PL PL16703768.8T patent/PL3253874T3/pl unknown
- 2016-02-08 US US15/549,072 patent/US10385338B2/en active Active
- 2016-02-08 ES ES16703768T patent/ES2918975T3/es active Active
- 2016-02-08 CA CA2975750A patent/CA2975750C/en active Active
- 2016-02-08 WO PCT/EP2016/052652 patent/WO2016124793A1/en not_active Ceased
- 2016-02-08 AU AU2016214244A patent/AU2016214244B2/en active Active
- 2016-02-08 EP EP16703768.8A patent/EP3253874B1/en active Active
-
2017
- 2017-08-01 IL IL253773A patent/IL253773B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10385338B2 (en) | 2019-08-20 |
| AU2016214244A1 (en) | 2017-08-17 |
| AU2016214244B2 (en) | 2022-04-07 |
| IL253773B (en) | 2021-09-30 |
| CA2975750A1 (en) | 2016-08-11 |
| CA2975750C (en) | 2023-06-13 |
| EP3253874A1 (en) | 2017-12-13 |
| ES2918975T3 (es) | 2022-07-21 |
| WO2016124793A1 (en) | 2016-08-11 |
| IL253773A0 (en) | 2017-09-28 |
| US20180016577A1 (en) | 2018-01-18 |
| EP3253874B1 (en) | 2022-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201704732B (en) | Cyclic dinucleotides useful for the treatment of inter alia cancer | |
| IL259996A (en) | Combinations for cancer treatment | |
| LT3122358T (lt) | Egfr ir cmet inhibitorių deriniai, skirti vėžio gydymui | |
| SG11201609652RA (en) | Treatment of polybacterials infections | |
| GB201502137D0 (en) | Treatment | |
| GB201522243D0 (en) | Treatment | |
| IL259178A (en) | Methods for treating muscular dystrophy | |
| GB201519450D0 (en) | Novel treatment | |
| IL255498A (en) | Treatment of pruritus | |
| GB201408297D0 (en) | Treatment of cancer | |
| KR20180084983A (ko) | 암의 치료를 위한 피리미도-피리미다지논의 용도 | |
| IL253773A0 (en) | Treatment of dystrophy of the facial, back and arm muscles | |
| GB201508841D0 (en) | Treatment | |
| ZA201606921B (en) | Use of xanthophylls for the treatment of cancers | |
| GB201522433D0 (en) | Cancer treatment | |
| IL252774A0 (en) | A pharmaceutical preparation for the treatment of fungus | |
| GB201503008D0 (en) | Treatment | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| IL255167A0 (en) | Compounds for the treatment of cancer | |
| ZA201704589B (en) | Compounds for the treatment of cancer | |
| GB201512139D0 (en) | Methods of treatment | |
| GB201417456D0 (en) | Treatment of cancer | |
| GB201512723D0 (en) | Treatment of cancer | |
| GB201507928D0 (en) | Treatment of cancer | |
| GB201504617D0 (en) | Treatment of cancer |